Table 2.
The clinical parameters between the two groups after propensity score match and inverse probability of treatment weighting
|
PSM
|
IPTW
|
|||||
|
non-CC group (n = 105)
|
CC-group (n = 105)
|
P
value
|
non-CC group (n = 130)
|
CC-group (n = 135)
|
P
value
|
|
| Gender, n (%) | 0.762 | 0.970 | ||||
| Male | 75 (71.4) | 73 (69.5) | 89.4 (68.5) | 92.6 (68.7) | ||
| Female | 30 (28.6) | 32 (30.5) | 41.1 (31.5) | 42.2 (31.3) | ||
| Age | 0.692 | 0.993 | ||||
| mean (SD) | 57.7 (11.8) | 58.3 (9.7) | 58.2 (11.2) | 58.2 (9.7) | ||
| Primary location, n (%) | 0.849 | 0.996 | ||||
| Up | 3 (2.9) | 2 (1.9) | 4.9 (3.8) | 4.9 (3.7) | ||
| Middle | 52 (49.5) | 50 (47.6) | 61.0 (46.7) | 63.8 (47.3) | ||
| Low | 50 (47.6) | 53 (50.5) | 64.6 (49.5) | 66.1 (49.0) | ||
| Pathology, n (%) | 0.903 | 0.999 | ||||
| Well-differentiated | 5 (4.8) | 5 (4.8) | 6.3 (4.9) | 6.6 (4.9) | ||
| Moderately-differentiated | 79 (75.2) | 75 (71.4) | 94.0 (72.0) | 97.9 (72.6) | ||
| Poorly-differentiated | 12 (11.4) | 13 (12.4) | 16.6 (12.7) | 17.0 (12.6) | ||
| Others | 9 (8.6) | 12 (11.4) | 13.6 (10.4) | 13.3 (9.9) | ||
| CEA, n (%) | 0.428 | 0.997 | ||||
| Normal | 51 (48.6) | 58 (55.2) | 64.1 (49.1) | 66.8 (49.5) | ||
| Unnormal | 45 (42.9) | 42 (40.0) | 55.2 (42.3) | 56.7 (42.1) | ||
| unidentified | 9 (8.6) | 5 (4.8) | 11.2 (8.6) | 11.3 (8.4) | ||
| T stage, n (%) | 0.568 | 0.992 | ||||
| < T3c | 41 (39.0) | 37 (35.2) | 48.0 (36.8) | 49.7 (36.9) | ||
| > T3b | 64 (61.0) | 68 (64.8) | 82.5 (63.2) | 85.1 (63.1) | ||
| N stage, n (%) | 0.097 | 0.176 | ||||
| N0 | 10 (9.5) | 4 (3.8) | 12.1 (9.3) | 6.7 (5.0) | ||
| N+ | 95 (90.5) | 101 (96.2) | 118.4 (90.7) | 128.1 (95.0) | ||
| Tumor length (mm) | 0.916 | 0.983 | ||||
| mean (SD) | 48.6 (13.0) | 48.4 (13.2) | 48.9 (12.5) | 48.9 (13.5) | ||
| Tumor thickness (mm) | 0.484 | 0.999 | ||||
| mean (SD) | 16.6 (5.0) | 16.0 (7.0) | 16.4 (4.9) | 16.4 (7.2) | ||
| MRF, n (%) | > 0.99 | 0.865 | ||||
| Negative | 23 (21.9) | 23 (21.9) | 29.7 (22.8) | 29.5 (21.9) | ||
| Positive | 82 (78.1) | 82 (78.1) | 100.7 (77.2) | 105.3 (78.1) | ||
| EMVI, n (%) | 0.771 | 0.998 | ||||
| Negative | 35 (33.3) | 37 (35.2) | 46.4 (35.6) | 48.0 (35.6) | ||
| Positive | 70 (66.7) | 68 (64.8) | 84.0 (64.4) | 86.8 (64.4) | ||
| Numbers of high-risk factor, n (%) | 0.510 | 0.883 | ||||
| 1 | 31 (29.5) | 26 (24.8) | 36.5 (28.0) | 35.1 (26.0) | ||
| 2 | 37 (35.2) | 45 (42.9) | 51.2 (39.2) | 56.9 (42.2) | ||
| 3 | 37 (35.2) | 34 (32.4) | 42.8 (32.8) | 42.8 (31.7) | ||
| Interval time (d) | 0.659 | 0.819 | ||||
| mean (SD) | 74.4 (20.0) | 75.6 (18.4) | 75.5 (25.1) | 74.8 (17.7) | ||
PSM: Propensity score match; IPTW: Inverse probability of treatment weighting; CC: Consolidation chemotherapy; SD: Standard deviation; CEA: Carcinoembryonic antigen; MRF: Mesorectal fascia; EMVI: Extralmural venous invasion.